Chimeric Therapeutics Limited has released a press release.
Chimeric receives $1.62M advance on FY26 R&D tax incentive
Earlier from Chimeric Therapeutics
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program